At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNS Marinus Pharmaceuticals
Post-Market Trading 06-17 19:43:53 EDT
1.45
-0.01
-1.02%
盘后1.46
+0.01+0.69%
18:11 EDT
High1.57
Low1.36
Vol2.60M
Open1.39
D1 Closing1.47
Amplitude14.33%
Mkt Cap79.65M
Tradable Cap54.74M
Total Shares54.93M
T/O3.84M
T/O Rate6.89%
Tradable Shares37.75M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Buy Rating on Marinus Pharmaceuticals: Promising Epilepsy Treatment Trials and Expansion Potential for ZTALMY Franchise
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.